(Q49240531)

19 February 2018

title

Defining a test for HER-2/neu evaluation in breast cancer in the diagnostic setting. (English)

1 reference

19 February 2018

author name string

Hanna WM

1

1 reference

19 February 2018

Kahn HJ

2

1 reference

19 February 2018

Pienkowska M

3

1 reference

19 February 2018

Blondal J

4

1 reference

19 February 2018

Seth A

5

1 reference

19 February 2018

Marks A

6

1 reference

19 February 2018

publication date

1 July 2001

1 reference

19 February 2018

published in

Modern Pathology

1 reference

19 February 2018

volume

14

1 reference

19 February 2018

page(s)

677-685

1 reference

19 February 2018

issue

7

1 reference

19 February 2018

https://scigraph.springernature.com/pub.10.1038/modpathol.3880372

exact match

0 references

cites work

The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880372

The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880372

Use of methodological standards in diagnostic test research. Getting better but still not good.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880372

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880372

Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880372

7 January 2021

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880372

7 January 2021

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880372

7 January 2021

Testing for erbB-2 by immunohistochemistry in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880372

7 January 2021

erbB-2 oncoprotein expression in breast carcinoma. Poor prognosis associated with high degree of cytoplasmic positivity using CB-11 antibody

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880372

7 January 2021

Increased HER2 with U.S. Food and Drug Administration-approved antibody

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880372

7 January 2021

The quality of Her-2/Neu predictive immunohistochemistry: something FISHy?

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880372

7 January 2021

Quantitative PCR analysis of c-erb B-2 (HER2/neu) gene amplification and comparison with p185(HER2/neu) protein expression in breast cancer drill biopsies

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880372

7 January 2021

Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880372

7 January 2021

Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880372

7 January 2021

10.1038/MODPATHOL.3880372

Identifiers

DOI

1 reference

19 February 2018

Dimensions Publication ID

0 references

1 reference

19 February 2018